NR1H4 and Insulin resistance: Recent research provides compelling evidence suggesting that antagonism of intestinal FXR signaling improves glucose metabolism, alleviates insulin resistance, and may improve nonalcoholic fatty liver disease (Gonzalez et al., 2017; Han, 2018; Sun et al., 2018; van Zutphen et al., 2019).